BDSI News and Press, BioDelivery Sciences International Inc.

35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the developm...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Berkshire Hathaway to acquire all outstanding Alleghany shares for $848.02 per share in cash, for a total equity value of approximately $11.6 billion. This is one of the five largest acquisitions in Berkshire's history and it ends Buffett's six-year drought of large acquisitions. ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

SA readers gravitated to extremes last week, taking notice of both smaller newsmakers and megacap safe havens. The dynamic came as investors looked for potential winners in an uncertain market that saw stocks whipsawed by the conflict in Ukraine. According to an analysis of portfolio addition...

BioDelivery Sciences International (BDSI), a specialty pharmaceutical company focused on chronic conditions, announced the U.S. launch of its oral migraine therapy Elyxybtm. Also known as celecoxib oral solution, Elyxybtm is the first and only oral solution approved by the U.S. Food and Drug ...

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences Internat...

Intel to acquire Tower Semiconductor for $53 a share, representing a premium of almost 60% to Tower's closing price the previous day. Madison Dearborn Partners to acquire MoneyGram International for $11 per share, representing a premium of approximately 50% to MoneyGram’s unaff...

Collegium Pharmaceutical has seen a decent 2021, but starts 2022 with a big and interesting deal. Investors are highly attracted to diversification and in anticipation of huge synergies. This looks compelling, yet the earnings situation will likely become complicated for quite a w...